Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LXI-15029 Monotherapy and Combination with Exemestane in Advanced Solid Tumors
NCT03125746Phase 1Unknown
- Sponsor
- Shandong Luoxin Pharmaceutical
- Start
- Jun 2017
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of LXI-15029 in solid tumor and breast cancer (2 arms), sponsored by Shandong Luoxin Pharmaceutical. Primary endpoint: Number of participants with adverse events. Status: unknown.
02
Drugs
LXI-15029
03
Conditions
solid tumorbreast cancer
Beyond the preview
Go deeper on NCT03125746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03125746.